NKGen Biotech, Inc. announces the successful completion of acquiring a controlling stake in NKMax Co., Ltd.
The acquisition grants NKGen full control over global manufacturing infrastructure and intellectual property assets.
Approximately $16.9 million paid to acquire a 65% equity stake in a debt-free NKMax, funded through 2026 by AlpineBrook Capital GP 1 Limited and NKGen CEO Dr. Paul Y. Song.
Transformative Acquisition
NKGen gains full control of global manufacturing and IP assets through acquiring a majority stake in NKMax.
Financial Support
Funding provided by AlpineBrook Capital GP 1 Limited and NKGen CEO Dr. Paul Y. Song to ensure continued operations through 2026.
Strategic Partnership
AlpineBrook's confidence in NKGen's long-term growth demonstrated through substantial funding for the acquisition.
- The acquisition marks a pivotal moment in NKGen's transformation into a self-sustaining cell therapy company.
- NKGen's control over key manufacturing and IP assets solidifies its position as a leader in NK cell therapeutics.
With the acquisition of NKMax, NKGen Biotech, Inc. is poised for significant growth and expansion in the global biotechnology market, focusing on innovative NK cell therapeutics.